ZBTB16 Antibodies

Zinc finger and BTB domain-containing protein 16 (ZBTB16)

Acts as a transcriptional repressor (PubMed:24359566). May play a role in myeloid maturation and in the development and/or upkeep of other differentiated tissues.

Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:14528312). .

Gene Information

Human
Gene Name:	ZBTB16
Uniprot:	Q05516
Entrez:	7704

Family

Belongs to:
krueppel C2H2-type zinc-finger protein family

Alternative Names

PLZF; PLZFzinc finger and BTB domain-containing protein 16; ZBTB16; zinc finger and BTB domain containing 16; zinc finger protein 145 (Kruppel-like, expressed in promyelocytic leukemia); Zinc finger protein 145; Zinc finger protein PLZF; ZNF145; ZNF145Promyelocytic leukemia zinc finger protein

Molecular Weight

Mass (kDA):
74.274 kDA

Genomic Context

Human
Location:	11q23.2
Sequence:	11; NC_000011.10 (114059576..114256770)

Tissue Specificity

Within the hematopoietic system, PLZF is expressed in bone marrow, early myeloid cell lines and peripheral blood mononuclear cells. Also expressed in the ovary, and at lower levels, in the kidney and lung.

Subcellular Localizations

Nucleus. Nucleus, nuclear body.

Diseases

• Leukemia
• Acute Promyelocytic Leukemia
• Malignant Neoplasms
• Neoplasms
• Chromosomal Translocation
• Myeloid Leukemia
• Cell Transformation, Neoplastic
• Leukemia, Myelocytic, Acute
• Leukemogenesis
• Growth Retardation
• Malignant Paraganglionic Neoplasm
• Melanoma

• Lymphoma
• Chimera Disorder
• Tissue Adhesions
• Anemia
• Infertility
• Acute Lymphocytic Leukemia
• L1 Acute Lymphoblastic Leukemia

Interacting Proteins

• CEP70
• COG6
• EEF1A1
• Gne
• GOLGA2

• Hoxa1
• IL6
• KRT40
• LDOC1
• PML

• TAB2
• TRAF1
• TRAF2
• TRIM27
• TRIM54

• VTA1

Pathways

• Cell Cycle
• Pathogenesis
• Cell Growth
• Spermatogenesis
• Localization
• Cell Development
• Cell Proliferation
• Chromatin Remodeling
• Regeneration
• Cell Cycle Arrest
• Cell Death
• Stem Cell Maintenance
• Ossification

• Nuclear Export
• Limb Development
• Cell Differentiation
• Oncogenesis
• Immune Response
• Secretion
• Cell Division

PTMs

• Phosphorylation
• Sumoylation
• Deacetylation

• Cleavage
• Methylation
• Acetylation

• Ubiquitination

Research Areas

• Cancer
• Innate Immunity
• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ZBTB16

Best Uses of the ZBTB16 Marker

ZBTB16, a biomarker could be the future of breast cancer treatment. In particular, the gene encodes for a zinc-finger transcription factor. This gene hinders cell growth and can improve the prognosis and treatment for breast cancer patients. But how do we find this biomarker? Here are some helpful tips. Continue reading to learn more about ZBTB16's marker and its potential.

ZBTB16 is a transcription factor for zinc fingers

ZBTB16's presence within tumor cells has been shown to significantly inhibit the growth of these cancer cells. Furthermore, overexpression or overexpression of the gene significantly increases the number of cancer cells that have entered the G2-M stage. These findings suggest that ZBTB16 may be utilized in the prevention and treatment of cancer. This finding is in agreement with other recent findings. In this article, we'll go over some of the most important results of these studies.

The structure of the translated protein of ZBTB16 is composed of nine C-terminal Kruppel-type zinc finger domains, three subdomains of the RD2-type and a BTB/POZ domain. The zinc finger domains facilitate specific DNA binding to target genes. The BTB/POZ Domain is known to play physiologically important roles and the RD2 domain is not as well recognized.

The role of ZBTB16 within the hypothalamus is largely unknown. The central nervous system is responsible for energy expenditure and feeding behaviors. However, it has been identified as a transcription factor in the hypothalamus, which is a region that is crucial to the balance of energy. Scientists have been able analyze the role of Zbtb16 by genetic targeting it in mice.

We performed a CoIP test to see how ZBTB16 interacts with other proteins. ZBTB16-expressing BT549 cells were used as co-IP. The total protein was extracted using low salt lysis buffer. We then incubated the extracts with antibodies against Flag M2, ZBTB28, and BCL6. The Co-IP complex was then identified by using an IgG antibody using Millpore SigmaTm Protein A/G Mixed Magnetic Bead System.

Using a synthetic protein, AAV5-hSyn-DIO-hM3Dq-mCherry, and a mouse model of the disease, ZBTB16 is a potential target for drug development. It was previously established that ZBTB16 is involved in the development neuronal brain tumors. It is an exciting and significant discovery that ZBTB16 was identified in human cells.

Recent studies indicate ZBTB16's expression is present in normal human breast tissues, but is downregulated in nine breast cancer cell lines. Breast cancer cells exhibit more than 50 percent promoter methylation. These results suggest that the methylation process is highly specific and inhibits ZBTB16's transcription. Moreover, 5-aza-2''deoxycytidine inhibits DNA methyltransferase, and thus decreases the amount of methylation in these cancer cells.

It inhibits cell proliferation.

Boster Bio develops antibodies for research purposes. They also offer immunological reagents as well as ELISA kits to identify biomarkers in the fields of neurobiology, developmental biology inflammation, cancer and neurosciences. These tests validate the reagents by testing them against a panel of cells and tissues with known concentrations. Boster Bio antibodies and kits have been proven to be highly specific against biomarkers, having a sensitivity of at least 0.1 picogram/ml.

It could be used to improve the prognosis or treatment of breast cancer.

The current approach to detect the immune response to chemotherapy or radiotherapy is not as accurate as is suggested. The immune response is essential for the effectiveness of chemotherapy and radiotherapy. Cancers that appear clinically have devised a variety of strategies to avoid the immune system and trigger tolerance or even immunosuppression. To combat this, new strategies are required to trigger the immune response. One method to improve the strength and quality of the immune response is nanovectorized radiotherapy.

Recent studies have demonstrated that tumors with infiltrating lymphocytes have improved prognosis. Recent efforts to define these immune cell subsets and to activate anti-tumor immunity in the host offer promising results and also raise some challenges. However, recent advances in these fields may serve as biomarkers in the near future. Inhibition of HR deficiency might also provide more precise direction for the use of existing immunotherapy treatments.

This novel method is being tested in humans. A variety of clinical trials have demonstrated that Boster Bio ZBTB16 may be utilized as a biomarker in improving the prognosis and treatment of breast cancer. Researchers are now conducting research to test Boster Bio ZBTB16 on multiple platforms including in vitro and in vivo cancer samples.

The research results also demonstrate that aging is the most significant risk factor for cancer around the world. It is not known what the role of aging plays in the immune surveillance against cancer. However, increasing evidence from experiments shows that the aging process increases the production of inflammation-related signals in mouse tissues. These studies aren't only ones to be done. Single cell RNA sequencing has also aid in the identification of lymphoid organs.

Despite the fact that there's no clinical trial for humans Boster Bio's findings ZBTB16 show that it could be used as a marker to aid in diagnosing and treating breast cancer. Researchers are working to define the IL7/IL7R signaling pathway within macrophages in the fetal stage and to determine the function of IL7R in myeloid-specification.

Researchers also discovered that a gene called TgXIST enhances the production of SLE-associated antibodies in male mice. These findings suggest that TgXist expression in male mice contributes to a feminine-like epigenetic profile of CD4+ T cells. Researchers also found that TgXIST expression in male mice resulted in female-like organ involvement.